CD40 expression in pancreatic cancer

Hepato-Gastroenterology

Volumn 60, Issue 128, 2013, Pages 2085-2093

  Unek, Tarkan ^a   Unek, Ilkay Tugba ^a   Agalar, Anil Aysal ^a   Sagol, Ozgul ^a   Ellidokuz, Hulya ^a   Ertener, Ozge ^a   Oztop, Ilhan ^a   Karademir, Sedat ^a   Yilmaz, Ugur ^a   Astarcioglu, Ibrahim ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

CD40; Pancreatic cancer; Prognostic marker; Survival

Indexed keywords

CD40 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTIGENS, CD40; BIOPSY; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893708344     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13421     Document Type: Article

References (72)

1. Hidalgo M: Pancreatic cancer. N Engl J Med 2010; 362(17):1605-1617.
2. Jemal A, Siegel R, Xu J, et al.: Cancer statistics. CA Cancer J Clin 2010; 60(5):277-300.
3. Beger HG, Rau B, Gansauge F, et al.: Treatment of pancreatic cancer: Challenge of the facts. World J Surg 2003; 27:1075-1084. (Pubitemid 37259985)
4. Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patient with advanced pancreas cancer: a randomised trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
5. Ryan DP, Grossbard ML: Pancreatic cancer: local success and distant failure. Oncologist 1998; 3:178-188. (Pubitemid 28307449)
6. Sultana A, Smith CT, Cunningham D, et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25:2607-2615. (Pubitemid 47041235)
7. Rivera F, López-Tarruella S, Vega-Villegas ME, et al.: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009; 35(4):335-339.
8. Nakamura M, Wada J, Suziki H, et al.: Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. Anticancer Res 2009; 29(3):831-836.
9. Armitage RJ, Fanslow WC, Strockbine L, et al.: Molecular and biological characterization of murine ligand for CD40. Nature 1992; 357(6373):80-82.
10. Foy TM, Aruffo A, Bajorath J, et al.: Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14:591-617. (Pubitemid 26130658)
11. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
12. Young LS, Eliopoulos AG, Gallagher NJ, et al.: CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19:502-506. (Pubitemid 28518027)
13. Eliopoulos AG, Young LS: The role of the CD40 pathway in the pathogenesis and treatment of cancer. Current Opinion in Pharmacol 2004; 4:360-367. (Pubitemid 38987062)
14. Aganthanggelou A, Niedobitek G, Chen R, et al.: Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995; 147:1152-1160.
15. Sbih-Lammali F, Clausse B, Ardila-Osorio H, et al.: Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999; 59:924-930. (Pubitemid 29086750)
16. Posner MR, Cavacini LA, Upton MP, et al.: Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999; 5:2261-2270. (Pubitemid 29399286)
17. Cao W, Cavacini LA, Tillman KC, et al.: CD40 function in squamous cell cancer of the head and neck. Oral Oncology 2005; 41:462-469. (Pubitemid 40692846)
18. Costello A, Rey-Hipolito C, Patel A, et al.: Thyroid cancers Express CD40 and CD40 Ligand: Cancers that Express CD40 Ligand may have a greater risk of recurrence in young patients. Thyroid 2005; 15:105-113. (Pubitemid 40344356)
19. Yamada M, Shiroko T, Kawaguchi Y, et al.: CD40-CD40 Ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and FAS expression and proliferation of human non-small cell lung tumors. Int J Cancer 2001; 92:589-599. (Pubitemid 32319435)
20. Sabel MS, Yamada M, Kawaguchi Y, et al.: CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 2000; 49(2):101-108. (Pubitemid 30431646)
21. Ishikawa K, Miyamoto M, Yoshioka T, et al.: Up-regulation of CD40 with Juxtacrine activity in human nonsmall lung cancer cells corraletes with poor prognosis. Cancer 2008; 113:530-541.
22. Tong AW, Papayoti MH, Netto G, et al.: Growth-inhibitory effects of CD40 Ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 7:691-703. (Pubitemid 32707996)
23. Wingett DG, Vestal RE, Forcier K, et al.: CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of FAS-mediated apoptosis. Breast Cancer Res Treat 1998; 50:27-36. (Pubitemid 28438858)
24. Hirano A, Longo DL, Taub DD, et al.: Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93(93):2999-3007. (Pubitemid 29200792)
25. Baxendale AJ, Dawson CW, Stewart SE, et al.: Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005; 24:7913-7923. (Pubitemid 41715197)
26. Gallagher NJ, Eliopoulos AG, Agathangelo A, et al.: CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. J Clin Pathol: Mol Pathol 2002; 55:110-120. (Pubitemid 34293413)
27. Melichar B, Patenia R, Gallardo S, et al.: Expression of CD40 and growth inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 2007; 104:707-713. (Pubitemid 46240267)
28. Ghamande S, Hylander BL, Oflazoglu E, et al.: Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61:7556-7562. (Pubitemid 32995048)
29. Jiang E, He X, Chen X, et al.: Expression of CD40 in ovarian cancer and adenovirus-mediated CD40 ligand therapy on ovarian cancer in vitro. Tumori 2008; 94(3):356-361.
30. Hess S, Engelmann H: A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 1996; 183:159-167. (Pubitemid 26028755)
31. Altenburg A, Baldus SE, Smola H, et al.: CD40 Ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-γ. J Immunol 1999; 162:4140-4147. (Pubitemid 29314799)
32. Hill SC, Youde SJ, Man S, et al.: Activation of CD40 in cervical carcinoma cells fascilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005; 174:41-50. (Pubitemid 40007390)
33. Paulie S, Ehlin-Henriksson B, Mellstedt H, et al.: A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 1985; 20(1):23-28. (Pubitemid 15238919)
34. Cooke PW, James ND, Ganesan R, et al.: CD40 expression in bladder cancer. J Pathol 1999; 188:38-43. (Pubitemid 29197312)
35. Jakobson E, Jönsson G, Björck P, et al.: Stimulation of CD40 in human bladder carcinoma cells inhibits anti-fas/apo-1 (CD95)-induced apoptosis. Int J Cancer 1998; 77:849-853. (Pubitemid 28378132)
36. Bugajska U, Georgopoulos NT, Southgate J, et al.: The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002; 94:1381-1395. (Pubitemid 35154143)
37. Rokhlin O, Bishop G, Hostager B, et al.: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57:1758-1768. (Pubitemid 27199671)
38. Kluth B, Hess S, Engelmann H, et al.: Endothelial expression of CD40 in renal cell carcinoma. Cancer Research 1997; 57:891-899. (Pubitemid 27098014)
39. Bussolati B, Russo S, Deambrosis I, et al.: Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer 2002; 100:654-661. (Pubitemid 34832974)
40. Shorts L, Weiss JM, Lee JK, et al.: Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 2006; 176(11):6543-6552. (Pubitemid 43787836)
41. Viac J, Schmitt D, Claudy A: CD40 expression in epidermal tumors. Anticancer Res 1997; 17(1B):569-572. (Pubitemid 27105529)
42. van den Oord JJ, Maes A, Stas M, et al.: CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996; 149:1953-1961. (Pubitemid 26415214)
43. Thomas WD, Smith MJ, Si Z, et al.: Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer 1996; 68(6):795-801. (Pubitemid 27062043)
44. von Leoprechting A, van der Bruggen P, Pahl HL, et al.: Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999; 59:1287-1294. (Pubitemid 29136260)
45. Pirozzi G, Lombari V, Zanzi D, et al.: CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. Int Immunol 2000; 12(6):787-795. (Pubitemid 30410451)
46. Kalbasi A, Fonsatti E, Natali PG, et al: CD40 expression by human melanocyte lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870, 893. J Immunother 2010; 33(8):810-816.
47. Pammer J, Plettenberg A, Weninger W, et al.: CD40 antigen is expressed by endothelial cells and tumor cells in kaposi's sarcoma. Am J Pathol 1996; 148:1387-1396. (Pubitemid 26135883)
48. Ottaiano A, De Chiara A, Perrone F, et al.: Prognostic value of CD40 in adult soft tissue sarcomas. Clin Cancer Res 2004; 10:2824-2831. (Pubitemid 38509162)
49. Lollini PL, Landuzzi L, Frabetti F, et al.: Expression of functional CD40 on human osteosarcoma and ewing's sarcoma cells. Clin Cancer Res 1998; 4:1843-1849. (Pubitemid 28369166)
50. Lo SS, Wu CW, Chi CW, et al.: High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis. Hepatogastroenterology 2005; 52:1902-1904.
51. Li R, Chen WC, Pang XQ, et al.: Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci 2009; 10:3900-3917.
52. Wu Y, Wang L, He X, et al.: Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Cellular Immunol 2008; 253:102-109.
53. Georgopoulos NT, Merrick A, Scott N, et al.: CD40-mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing. Int J Cancer 2007; 121:1373-1381. (Pubitemid 47293808)
54. Sugimoto K, Shiraki K, Ito T, et al.: Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 1999; 30:920-926. (Pubitemid 29458280)
55. Holub M, Zakeri SM, Lichtenberger C, et al.: Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2003; 15(2):119-126. (Pubitemid 36269774)
56. Beatty GL, Chiorean EG, Fishman MP, et al.: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-1616.
57. He S, Zhao H, Fei M, et al.: Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Oncol Rep 2012; 28:262-268.
58. Shoji Y, Miyamoto M, Ishikawa K, et al.: The CD40-CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma. J Surg Oncol 2011; 103(3):230-238.
59. Ingersoll SB, Langer F, Walker JM, et al.: Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis. Clin Exp Metastasis 2009; 26:829-837.
60. Palmer DH, Hussain SA, Ganesan R, et al.: CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep 2004; 12(4):679-682.
61. Dallman C, Johnson PWM, Packham G: Differential regulation of survival by CD40. Apoptosis 2003; 8:45-53.
62. Eliopoulos AG, Davies C, Knox PG, et al.: CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20(15):5503-5515. (Pubitemid 30482887)
63. Eliopoulos AG, Dawson CW, Mosialos G, et al.: CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996; 13(10):2243-2254. (Pubitemid 26411575)
64. Georgopoulos NT, Steele LP, Thomson MJ, et al.: A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006; 13:1789-1801. (Pubitemid 44390865)
65. Davies CC, Mason J, Wakelam MJO, et al.: Inhibition of phosphotidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004; 279(2):1010-1019. (Pubitemid 38082622)
66. Ryschich E, Märten A, Schmidt E, et al.: Activating anti-CD40 antibodies induce tumor invasion by cytotoxic T-lymphocytes and inhibition of tumor growth in experimental liver cancer. Eur J Cancer 2006; 42:981-987.
67. Alexandroff AB, Jackson AM, Paterson T, et al.: Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Molecular Immunol 2000; 37:515-526. (Pubitemid 32001693)
68. Ottaiano A, Pisano C, De Chiara A, et al.: CD40 activation as potential tool in malignant neoplasms. Tumori 2002; 88(5):361-366. (Pubitemid 35356100)
69. Tong AW, Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10(1):1-13. (Pubitemid 36222071)
70. Vonderheide RH: Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13(4):1083-1088.
71. Fonsatti E, Maio M, Altomonte M, et al.: Biology and clinical applications of CD40 in cancer treatment. Semin Oncol 2010; 37(5):517-523.
72. Vonderheide RH, Dutcher JP, Anderson JE, et al.: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19(13):3280-3287. (Pubitemid 32591446)